

Supplemental Table S3. Recommended Dosage Adjustments of RDA DPP4 Inhibitors for Patients with Impaired Kidney Function

Class	DPP4 inhibitor	Urinary excretion	Standard dosing	Recommended dosage in CKD
RDA	Sitagliptin	79%	100 mg qd	30 ≤ eGFR < 50 mL/min/1.73 m ² : 50 mg qd eGFR < 30 mL/min/1.73 m ² : 25 mg qd
	Vildagliptin	85%	50 mg bid	30 ≤ eGFR < 50 mL/min/1.73 m ² : 50 mg qd eGFR < 30 mL/min/1.73 m ² : 50 mg qd
	Saxagliptin	75%	5 mg qd	30 ≤ eGFR < 50 mL/min/1.73 m ² : 2.5 mg qd eGFR < 30 mL/min/1.73 m ² : 2.5 mg qd
	Alogliptin	76%	25 mg qd	30 ≤ eGFR < 60 mL/min/1.73 m ² : 12.5 mg qd eGFR < 30 mL/min/1.73 m ² : 6.25 mg qd
	Anagliptin	76%	25 mg qd	30 ≤ eGFR < 60 mL/min/1.73 m ² : 12.5 mg qd eGFR < 30 mL/min/1.73 m ² : 6.25 mg qd

RDA, renal dose-adjusted; DPP4, dipeptidyl peptidase-4; CKD, chronic kidney disease; qd, once daily; eGFR, estimated glomerular filtration rate; bid, twice daily.